An amplification-free, innovative, multiplex assay to quantify microRNAs in single cells from COPD patients
Article 2022 en
Authors
VH
Van Cong Nhan Ho
JB
J R Baker
KW
K R Willison
Abstract
1 min read
<b>Introduction:</b> Chronic obstructive pulmonary disease (COPD) is associated with accelerated ageing of the lung. In COPD, microRNA(miR)-21 is up-regulated in plasma and miR-34a in epithelial cells. Microfluidic technology enables multiplexing of miRNA assays with single cell analysis to absolutely quantify miRNAs in scarce samples. <b>Aim:</b> To develop a multiplex assay to absolutely quantify miR-21 and miR-34a molecules from the same cell <b>Methods:</b> A multiplex chip was microarrayed with miR-21 and miR-34a capture probes. Complimentary reporter probes were tagged with different fluorophores. Small airway fibroblasts (SAF) and epithelial cells (SAEC) (50 cells/experiment) were optically manipulated and lysed. Single miR-21 and miR-34a molecules released from the same cell were imaged using microscopy. <b>Results:</b> MiR-21 expression in COPD was significantly elevated (SAF: 83.5±1.2 x10<sup>3</sup> and SAEC: 102±0.9 x10<sup>3</sup>, p<0.05) compared to non-smokers (NS) (SAF: 27.5±0.3 x10<sup>3</sup> and SAEC: 23.5±0.4 x10<sup>3</sup>) molecules/cell. MiR-34a expression in COPD was significantly increased (SAF: 65.1±0.7 x10<sup>3</sup> and SAEC: 79.8±0.4 x10<sup>3</sup>, p<0.05) compared to NS (SAF: 3.1±0.01 x10<sup>3</sup> and SAEC: 7.42±0.1 x10<sup>3</sup>) molecules/cell. Both miRNAs expression were positively correlated in SAF and SAEC but reduced in COPD SAF (NS: r=0.81, p<0.0001 vs COPD: r= 0.66, p<0.0001, n=5) and SAEC (NS: r=0.86, p<0.0001 vs COPD: r=0.64, p<0.0001, n=5). <b>Conclusion:</b> Absolute expression of miRNAs can be quantified from the same cell using a microfluidic multiplex assay. Expression of miR-21 and miR-34a in a single cell are positively correlated but differ between COPD and NS subjects. Thus, this novel tool may be used to identify miRNAs as COPD biomarkers.
Discussion(0)
No comments yet. Be the first to comment.